Favorites and recent references stay on this device. No patient data is stored.
Choose the species
One selection filters the source overview, clinical facts, reports and dose calculator. Literature references are not species-filtered.
Choose one species for its overview and dose calculator, or all species to browse the full evidence.
Source overview
Recorded excerpts for one species. Each dose remains a separate source entry; no regimen is selected.
Choose one species to view its source overview. All-species evidence remains available below.
View full clinical evidence and sources ↓Clinical evidence
Pending clinical review (PROPOSED)Rule-based (RULE_BASED)— applies to the facts and dose entries in this species selection; individual source records retain their own status.
Indications2
Nonresectable grade II/III cutaneous mast cell tumors; atopic dermatitis (limited studies, moderate efficacy — mast-cell pathogenesis implication)
DogExtra-label (EXTRA_LABEL)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: Nonresectable grade II/III cutaneous mast cell tumors; atopic dermatitis (limited studies, moderate efficacy — mast-cell pathogenesis implication) — Conditional approval (Kinavet-CA1); atopic use extra-label
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Investigational only — poor tolerance
CatExtra-label (EXTRA_LABEL)1 source record · View provenance
- Cat · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: Investigational only — poor tolerance — Extra-label; caution
- Cat · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Dose regimens2
This calculator performs arithmetic only on the sourced dosing field shown for each result — it does not verify the field's accuracy, does not select which field to use for a patient, and does not replace a veterinarian's order. Not for clinical use. Confirm every result against the primary source before dispensing.
Choose one species above to view its dose calculator.
Adverse effects130
GI disturbance — Main canine effect
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Reversible protein loss (protein-losing enteropathy/nephropathy pattern) — Documented — monitor proteins
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Vomiting/diarrhea (prominent), proteinuria, neutropenia — Cats particularly prone
CatNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Cat · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Anaemia NOS50 reports
- Elevated alanine aminotransferase (ALT)39 reports
- Anorexia35 reports
- Elevated serum alkaline phosphatase (SAP)34 reports
- Hypoalbuminaemia32 reports
- Neutropenia29 reports
- Vomiting29 reports
- Leucopenia NOS21 reports
- Proteinuria19 reports
- Depression18 reports
- Diarrhoea17 reports
- Death by euthanasia15 reports
Cat
- Anorexia5 reports
- Elevated creatinine5 reports
- Death3 reports
- Death by euthanasia3 reports
- Elevated blood urea nitrogen (BUN)3 reports
- Renal failure3 reports
- Hypoalbuminaemia2 reports
- Vomiting2 reports
- Weight loss2 reports
- Acute renal failure1 reports
- Anaemia NOS1 reports
- Anaphylaxis1 reports
Monitoring1
Serum protein (albumin) + urine protein periodically; GI signs; CBC in cats if used
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Monitoring Parameters · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Precautions5
No formal contraindications reported; monitor albumin/urine protein periodically during therapy
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Contraindications & Warnings table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
The Kit-selective sibling of toceranib: same target family (Mast cell tumors), different selectivity profile and regulatory status (conditional approval in US as Kinavet-CA1 vs Palladia's full approval).
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
The atopic-dermatitis signal (same 12.5 mg/kg dose) is pharmacology teaching a lesson: if masitinib helps atopic dogs, mast cells matter in atopy.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Protein loss is the monitoring keystone (serum + urine) — the toxicity that defines patient retention.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Not in Plumb's 7th ed. (2011) — this file is Papich 4th ed.-based, like telmisartan.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Interactions1
None reported — (Limited data — standard TKI/CYP cautions theoretically apply)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pharmacokinetics2
Mechanism — TKI selective for c-Kit / stem-cell-factor pathway — direct antiproliferative action on mast cells
Other speciesNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Other species · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
MDR effect — May revert multidrug resistance in doxorubicin-resistant canine cancer cells (in vitro — unconfirmed clinically)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pregnancy / lactation considerations1
Not established; avoid (class expectation for antineoplastics).
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 476–477 — Pregnancy & Lactation · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Literature references18
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Comparative pathophysiology and molecular insights into cutaneous and non-cutaneous canine skin cancers: focus on melanoma, mast cell tumors, and squamous cell carcinoma.
Study summary not available in the imported record. Open the original citation to review the study.
- A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.
Study summary not available in the imported record. Open the original citation to review the study.
- c-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells.
Study summary not available in the imported record. Open the original citation to review the study.
- Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Study summary not available in the imported record. Open the original citation to review the study.
- Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration; Papich MG. Saunders Handbook of Veterinary Drugs. 4th ed. Saunders; 2015.
Owner information handout
Plain-language medication information to review with the owner. Open the handout to print it or download a PDF.